{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6OiYIKDA","lastupdate":"2020-08-17T00:00:00.000Z","update_date":"2020-08-17T00:00:00.000Z","lastModified":"Sep 7, 2024","active":1,"confidence_score":90,"confidence_score_reason":"markets, not claimed","urlname":"biokine-therapeutics","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$x3VtKi7H2a9rJSRpYrxB9Vw52Jw0JYLjkiJi4EoBUbh2JIP74xGVWd","name":"Biokine Therapeutics","oneliner":"Anticancer and Stem Cell Mobilization Drugs","registrar":"512976317","website":"https://biokine.com","careerspage":"","founded_month":7,"founded_year":2000,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/5550255","instagram":""},"social":["https://www.linkedin.com/company/5550255"],"flattenedsociallinks":"https://www.linkedin.com/company/5550255","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"1-10","employees_exact":4,"patent":0,"raised":1950000,"stage":"Mature","public_stage":"Mature","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"Biokine Therapeutics is a clinical-stage biopharmaceutical company developing novel drugs to treat cancer. \r\n\r\nFounded in 2000 by Prof. Amnon Peled, a leading cancer and stem cell biologist at Hadassah University Hospital, Biokine has completed many years of R&D and clinical research. The company is devoted to identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis. Biokine has developed a suite of unique approaches to target cancer and is conducting preclinical and clinical research on several molecules discovered and developed in-house. \r\n\r\nThe companys lead drug candidate, the high-affinity CXCR4 antagonist BKT140/BL8040, is currently in a phase 2a clinical trial for the treatment of refractory and relapsed acute myeloid leukemia (AML), as well as a phase 1 clinical trial for the mobilization of stem cells. The CXCR4 receptor plays a pivotal role in the regulation of certain cancers and inflammatory diseases and is critically involved in stem cell biology and tissue regeneration. BKT140/BL8040 was licensed to BioLineRx Ltd.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97289301015","country":null,"address":{"israeli":[{"id":"825afa01-23c5-47e6-a47f-52b536c37bf6","city":"Rehovot","type":null,"address":"Rehovot, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"fb8a155c-75e8-4c86-838a-50772d0f577c","date":"Oct 3, 2018","link":"https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-increases-stake-bl-8040-its-lead-oncology-platform","source":"ir.biolinerx.com","visible":1,"analysis":{"tags":"Acquisition, Investment","company":"BioLineRx Ltd.","layoffs":"Not mentioned","summary":"BioLineRx Ltd., a clinical-stage biopharmaceutical company, has announced an agreement with Biokine Therapeutics to increase its stake in its lead oncology platform, BL-8040, from 60% to 80%. The transaction involves an upfront payment of $10 million in cash and $5 million in restricted BioLineRx shares, with Biokine also eligible to receive up to $5 million in future milestone payments. The $10 million upfront payment is being financed in full via the receipt of $10 million in debt financing from Kreos Capital. The transaction is expected to close within the next 10 days.","partners":"Biokine Therapeutics","customers":"Not mentioned","investors":"Kreos Capital","confidence":9,"key_topics":["Oncology","Immunology","Clinical Development","Stake Increase","Debt Financing"],"date_of_event":"Oct. 3, 2018","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$10 million","structured_issues":["Investment","Acquisition"],"acquisition_amount":"$15 million","structuredIssuesShow":"#Investment  #Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"QQeFmNubZsffCzrJzoZQ2hsiJxYn7r6BvLAXA7gMy1MYuMRjnCnBFp","news_summary":"BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications  BioLineRx","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5fed5e29-0b8f-4c57-96c1-6373623f77a8","date":"Sep 7, 2016","link":"http://biokine.com/biolinerx-announces-clinical-research-collaboration-to-investigate-combination-of-bl-8040-with-atezolizumab-in-multiple-oncology-indications/","source":"biokine.com","visible":1,"analysis":{"tags":"clinical research collaboration","company":"BioLineRx Ltd.","layoffs":null,"summary":"BioLineRx has announced a clinical research collaboration with Genentech to investigate the combination of BL-8040 with Atezolizumab in multiple oncology indications. The Phase 1b studies will evaluate the clinical response, safety, and tolerability of the combination in hematologic malignancies and solid tumors.","partners":"Genentech","customers":null,"investors":null,"confidence":9,"key_topics":["BioLineRx","Genentech","BL-8040","Atezolizumab","Phase 1b studies"],"date_of_event":"2021-06-03","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"guP0G9XwXWHOJUswVbHMtpjftxvKXn7q4R8zbBL6nccjlMR0gjdo09","news_summary":"BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5fed5e29-0b8f-4c57-96c1-6373623f77a8","date":"Sep 7, 2016","link":"http://biokine.com/biolinerx-announces-clinical-research-collaboration-to-investigate-combination-of-bl-8040-with-atezolizumab-in-multiple-oncology-indications/","source":"biokine.com","visible":1,"analysis":{"tags":"clinical research collaboration","company":"BioLineRx Ltd.","layoffs":null,"summary":"BioLineRx has announced a clinical research collaboration with Genentech to investigate the combination of BL-8040 with Atezolizumab in multiple oncology indications. The Phase 1b studies will evaluate the clinical response, safety, and tolerability of the combination in hematologic malignancies and solid tumors.","partners":["Genentech"],"customers":null,"investors":null,"confidence":9,"key_topics":["BioLineRx","Genentech","BL-8040","Atezolizumab","Phase 1b studies"],"date_of_event":"2021-06-03","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oyjstt4E2pEvVpcxXw4p7Ed2eKgoICJML7hKQY0p6XoW3GGTizMb97","news_summary":"BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ad8d3f9b-e3cc-474b-b227-8f0295d80d5c","date":"Mar 29, 2016","link":"http://biokine.com/biolinerx-reports-successful-top-line-results-in-phase-2-trial-for-aml/","source":"biokine.com","visible":1,"analysis":{"tags":"clinical trial","company":"BioLineRx","layoffs":null,"summary":"BioLineRx has reported positive top-line results from its Phase 2 clinical trial for relapsed or refractory acute myeloid leukemia (AML). The company also identified a potential biomarker for future selection of BL-8040-responsive AML patients.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Phase 2 trial","AML","top-line results","biomarker","BL-8040"],"date_of_event":"2021-06-03","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Mj3lnkydi4ez1qdenaNintUQFaw75mcS3jeMPqXP97mUse94LqfgW4","news_summary":"BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8fa9f95a-6196-46b2-b8d9-b0e4b709f9ab","date":"Mar 18, 2009","link":"http://www.globes.co.il/en/article-1000435265","source":"www.globes.co.il","visible":1,"analysis":{"tags":"biotechnology, clinical study, research grant, cancer drug","company":"Biokine Therapeutics, Ltd.","layoffs":null,"summary":"Biokine Therapeutics, Ltd. has received a $1.2 million research grant from the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor. The funding will support a Phase I/IIa clinical study to test the safety and efficacy of the companys flagship product, cancer drug BKT140. The study has been initiated at the Sheba Medical Center. Biokine Therapeutics develops pharmaceuticals that control the activity of receptors for molecules called chemokines, which play a key role in the development of cancer and inflammatory diseases.","partners":null,"customers":null,"investors":"Office of the Chief Scientist of the Ministry of Industry, Trade and Labor","confidence":8,"key_topics":["Biokine Therapeutics","clinical study","research grant","cancer drug","Phase I/IIa"],"date_of_event":"March 18, 2009","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$1.2 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ISRwX3a8EqZIlYHFFkRYoR1idxQDvIa6pPPwsnSvMLL7QXogtbf94b","news_summary":"Cancer treatment co BioKine gets $1.2m grant","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"98cb8d7d-33eb-4c1b-a04e-e971b36727f5","date":"Jan 10, 2007","link":"http://www.globes.co.il/en/article-1000171631","source":"www.globes.co.il","visible":1,"analysis":{"tags":"cancer treatment","company":"Biokine","layoffs":null,"summary":"Biokine, a developer of cancer treatment, has raised NIS 2.5 million in investment. The company is currently in the process of para-clinical trials for its cancer drug. Biokine was founded in 2000 by Dr. Amnon Peled and Dr. Lior Carmon. It has received research grants and funding from the EU sixth framework program. The companys cancer drug targets a receptor over-expressed in various types of cancer cells, causing them to die.","partners":null,"customers":null,"investors":["Hadasit Bio Holdings Ltd.","Clal Biotechnology Industries Ltd.","Shmuel Cabilly"],"confidence":8,"key_topics":["cancer drug","fundraising","research grants","clinical trials","company history"],"date_of_event":"January 10, 2007","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"NIS 2.5 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"dd2bu2l1PWJUN1ajL7QxeVqA4r9DCa1H7dFJFXdvCPpP9B5SOceacI","news_summary":"Cancer treatment co Biokine raises NIS 2.5m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":5,"techcommunityinvolvement":null,"mediagallery":[{"id":"20111889-fe78-4175-9f00-dba9d49ae761","timestamp":"2016-06-16 12:17:01.000000","resources_type":1,"resources_title":"","resources_file_name":"$G3nST4ROXu4cX0KSWv8yy2aDqPFd97ZjknQpnSLvHycsw1Xh1F23A8","alt":"","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$G3nST4ROXu4cX0KSWv8yy2aDqPFd97ZjknQpnSLvHycsw1Xh1F23A8","url":"https://storage.googleapis.com/clean-finder-353810/$G3nST4ROXu4cX0KSWv8yy2aDqPFd97ZjknQpnSLvHycsw1Xh1F23A8"}],"tags":["stem-cells","biopharmaceutical","bioprocess","cancer","drug-discovery","doctors","autoimmune-diseases","patients","healthcare-providers"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2C"],"productstage":"Released","products":["BKT300","BKT140","BKT130"],"geomarkets":["United States"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":2,"lastfunding":"$1.2M","totalrounds":2,"fundingstage":"Mature","totalfunding":"$1.95M","publicinvestors":2,"lastpublicfunding":1200000,"totalpublicrounds":2,"totalpublicfunding":1950000},"team":[{"name":"Julian Levy","email":"julian.levy@biokine.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoMWjvecLDA","bounced":true,"claimed":0,"founder":0,"urlname":"julian-levy-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg5Y-D2wgM","position":"CEO","last_name":"Levy","claimtoken":"a8b7e4c86bc36eb7b7178b312966b246b26ab33020b93acc8a71a639298276b2","first_name":"Julian","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/julian-levy-51232b/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-08-17 12:19:55.000000","initials":"JL","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Amnon  Peled, Prof.","email":"amnon.peled@biokine.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwInm3dcJDA","bounced":false,"claimed":0,"founder":1,"urlname":"amnon-peled-prof","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDAieb4kwgM","position":"CEO/CSO and Founder","last_name":"Peled, Prof.","claimtoken":"4815ee4432bb428243ff1fc079e07feabf17b15bca90b23cb9dc5167a2b6508c","first_name":"Amnon ","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2020-08-17 12:20:16.000000","initials":"AP","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Orly  Eizenberg","email":"orly.eizenberg@biokine.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGh_IQIDA","bounced":false,"claimed":0,"founder":0,"urlname":"orly-eizenberg","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAsYXJngkM","position":"VP R&D","last_name":"Eizenberg","claimtoken":"78e17b147da455fca49265ef37b3f447cfb8fafc68d8c1856cedc5b74545d0e6","first_name":"Orly ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/orly-eizenberg-1276115/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2020-08-17 12:20:04.000000","initials":"OE","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverifydate":"2019-11-20T00:00:00.000Z","crunchbaseid":"biokine-therapeutics","lastupdator":"Orli Wollner","lastupdator_email":"orlushka@gmail.com","creator":null,"creator_email":null,"createdate":"2015-01-12T00:00:00.000Z","biverification":"Natalia Golczar","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODEtpP0Cgw","date":"Mar 2009","amount":"$1.2M","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Office of the Chief Scientist","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"640f06cb-0714-4f6c-b5aa-504b72d9ef1b","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1200000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCko46bCww","date":"Jan 2007","amount":"$750K","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Clal Biotechnology Industries (CBI)","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/cbi","logokey":"$fJl2RfhlVYviq9T0pSOI3rKMQTrLfwIf7Co69YLOBIKRfoeftdbWGk","tagline":null,"urlname":"/investor_page/cbi","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKG0pYwKDA","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"71397571-432a-479f-9521-16c300724e99","fundingsubtype":"Corporate VC","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$fJl2RfhlVYviq9T0pSOI3rKMQTrLfwIf7Co69YLOBIKRfoeftdbWGk","leadcaption":"","followupcaption":""},{"name":"Amnon Peled","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/amnon-peled","logokey":null,"tagline":"","urlname":"/investor_page/amnon-peled","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk8NCRCww","fundingtype":"Angel","leadpartner":null,"investmentid":"cc07a28e-0418-4338-a633-45ae7e1858fc","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":750000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"7/2000","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Biokine Therapeutics","logourl":"https://storage.googleapis.com/clean-finder-353810/$x3VtKi7H2a9rJSRpYrxB9Vw52Jw0JYLjkiJi4EoBUbh2JIP74xGVWd","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$x3VtKi7H2a9rJSRpYrxB9Vw52Jw0JYLjkiJi4EoBUbh2JIP74xGVWd","seoabout":"Biokine Therapeutics is a clinical-stage biopharmaceutical company developing novel drugs to treat cancer. \r\n\r\nFounded in 2000 by Prof. Amnon Peled, a lead...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]},{"title":"Healthcare","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"},{"title":"Providers","key":"0-0-1-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Cells","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Cells"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Cells"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals","Healthcare","Patients","Providers"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCko46bCww","date":"Jan 2007","amount":"$750K","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Clal Biotechnology Industries (CBI)","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/cbi","logokey":"$fJl2RfhlVYviq9T0pSOI3rKMQTrLfwIf7Co69YLOBIKRfoeftdbWGk","tagline":null,"urlname":"/investor_page/cbi","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKG0pYwKDA","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"71397571-432a-479f-9521-16c300724e99","fundingsubtype":"Corporate VC","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$fJl2RfhlVYviq9T0pSOI3rKMQTrLfwIf7Co69YLOBIKRfoeftdbWGk","leadcaption":"","followupcaption":""},{"name":"Amnon Peled","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/amnon-peled","logokey":null,"tagline":"","urlname":"/investor_page/amnon-peled","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk8NCRCww","fundingtype":"Angel","leadpartner":null,"investmentid":"cc07a28e-0418-4338-a633-45ae7e1858fc","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":750000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODEtpP0Cgw","date":"Mar 2009","amount":"$1.2M","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Office of the Chief Scientist","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"640f06cb-0714-4f6c-b5aa-504b72d9ef1b","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1200000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}